Clinical Trial Update: Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST [Phase 1]

View source ↗

Summary

Phase Ib trial updates on alternating Sunitinib and Regorafenib in metastatic/unresectable gastrointestinal stromal tumor (GIST); study completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Regorafenib (regorafenib)
• Sunitinib (sunitinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Gastrointestinal Stromal Tumor | Phase 1 | Status: COMPLETED | Results posted: 2019-09-12